Abstract:Omar Castaneda-Puglianini, 1 Julio C Chavez 2 1 Virginia Commonwealth University, Massey Cancer Center, Cellular Immunotherapies and Transplant Program, Richmond, VA, USA; 2 Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA Correspondence: Julio C Chavez Department of Malignant Hematology, Moffit Cancer Center, 12902 Magnolia Drive FOB, Tampa, FL, 33612, USA Email julio.c. Chimeric antigen receptor T-cell (CAR-T) therapy represents the most important advances in cancer immunotherapy, especially in hematological malignancies such as B-cell lymphomas. CAR-T cell therapy has significant activity in poor risk B-cell lymphomas. CAR-T cell therapy is associated with potentially life-threatening toxicities such as cytokine release syndrome (CRS) and neurotoxicity (NT). While CRS pathophysiology and management are well established, the understanding and treatment of NT continues to develop. All current CAR-T products approved for DLBCL have been associated with NT with some differences in their severity. As cell therapies continue to advance and its access broadening, it will be imperative for clinicians to be aware of the signs and symptoms of NT, its stratification and basic management. Keywords: CAR-T, neurotoxicity, ICANS, encephalopathy Immunotherapy with chimeric antigen receptor T-cell (CAR-T) therapy is one of the most important advances in the treatment of cancer and, particularly, hematologic malignancies. In lymphoma, CAR-T cells targeting CD19 have been widely developed resulting in three commercially available products and several ongoing clinical trials. 1 In diffuse large B-cell lymphoma (DLBCL), there are currently three CAR-T cell products approved (after at least 2 lines of therapy): axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel) and lisocabtagene ciloleucel (liso-cel). Axi-cel, tisa-cel and liso-cel are genetically modified anti-CD19 autologous T-cells that are designed to target CD19 in B-cell malignancies. Based on the ZUMA-1, JULIET and TRANSCEND-NHL-001 studies, all three showed prominent activity in poor risk relapsed/refractory DLBCL with an overall response rate (ORR) between 50% and 82% with many patients having a durable response. 2–5 The efficacy of CAR-T cell therapy is offset by potential class-effect toxicities that could be life-threatening and will require the implementation of appropriate measures to mitigate these side effects. CAR-T cell therapy is associated with high rates of unique toxicities, namely cytokine release syndrome (CRS) and neurotoxicity (NT). CRS is a well-known syndrome driven by a rapid release and expansion of inflammatory cytokines that leads to several systemic symptoms and clinical findings such as fevers, hypoxemia, constitutional symptoms, hypotension, tachycardia and organ dysfunction. 6,7 The pathophysiology and management of CRS is well described and standardized, and involves the use of anti-cytokine therapy (ie, tocilizumab) with/without steroids. This treatment strategy leads to a rapid resolution of symptoms. 6–8 Unlike CRS, the understanding of NT pathophysiology and management is less established and continues to evolve. 9 The pathophysiology of NT, currently known as immune effector cell-associated neurotoxicity syndrome (ICANS), continues to develop. Current knowledge highlights the disruption of the blood brain barrier (BBB) caused by inflammation and increased cytokines as a key initiating factors. 10 BBB disruption is triggered by endothelial cell activation as early event, which subsequently leads to BBB breakdown, increased permeability and coagulopathy as demonstrated in a mouse model. 11 In healthy states, angiopoietin-1 (ANG1) and −2 (ANG2) remain in normal ratios, hence preventing endothelial activation. During severe ICANS, levels of ANG2 and ANG2:ANG1 ratio are significantly increased representing a disruption of the BBB and capillary leak. 11 In addition, patients with severe ICANS had increased levels of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-a), interferon gamma (IFN-g) and interleukin (IL)-6 that are likely released by CD14+ myeloid derived suppressor cells (MDSCs) which are also increased during NT. 11,12 The presence of high levels of Von Willebrand Factor (WWF), high molecular weight WWF multimers and depleted ADAMTS 13 levels also supported the endothelial activated and coagulopathic state during severe ICANS. 11 Other mouse models demonstrated the role of MDSCs and monocytes in NT pathophysiology and their key role as main sources of the above-mentioned pro-inflammatory cytokines including IL-1. 13,14 Additionally, intratumoral interactions between CAR-T and macrophages/monocytes mediated by th -Abstract Truncated-

Abstract IA02: Diffuse large B-cell lymphoma and neurotoxicity following CAR-T cell immunotherapy: Contributing factors and blood-brain barrier impairment biomarkers

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.

Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma

Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicity

Abstract 3867: Identification of novel biomarkers of immune toxicity from CAR T-cell therapy using ultrasensitive NULISATM proteome technology

Abstract PR06: Comprehensive characterization of the non-tumor microenvironment of relapsed/refractory large B-cell lymphoma identifies patients with greatest benefit from CD19 CAR T-cell therapy

Clinical Features of Neurotoxicity Following CD19 CAR T-cell Therapy in Mantle Cell Lymphoma.

CART-AI-Radiomics: Survival and Neurotoxicity Prediction in B-Cell Lymphoma Patients Treated with CAR-T Cells through an Imaging Features-Based Model

Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

Abstract 882: Harnessing single cell multi-omics data to identify predictors of clinical outcome in CD19 CAR T cell therapy

Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma

The Mechanisms of Altered Blood–Brain Barrier Permeability in CD19 CAR T–Cell Recipients

PD-L1+ macrophage and tumor cell abundance and proximity to T cells in the pretreatment large B-cell lymphoma microenvironment impact CD19 CAR-T cell immunotherapy efficacy

Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT

Abstract A041: Vascular normalization improves the delivery and efficacy of CAR-T cells in mouse brain cancers

Clonal Hematopoiesis is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma.

Abstract 3619: Post CAR-T lymphocytosis as a surrogate of BCMA CAR-T expansion, response, and prognosis in multiple myeloma

Abstract B033: Excessive Chimeric Antigen Receptor signaling correlates with poor clinical outcomes

CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells

Abstract 4002: Investigating CAR-T cell efficacy and activation in the disseminated NALM6-luc human B-cell acute lymphoblastic leukemia model

Abstract A011: Modeling the coevolution of native and CAR T-cells in large B cell lymphoma reveals a potential biomarker for response to therapy